Welcome to Consumercide.com    | Regush on Cervical Cancer Vaccine
  Cervical Cancer Vaccine -- A Shameful Example of How Medical Research is Taking Dangerous Short-Cuts                        -By Nicholas Regush

                        Whenever you see or hear the word "breakthrough" in a medical news report,
                        duck for cover. Chances are someone’s imagination is hard at work.

                        The latest medical frenzy involved a vaccine aimed at cervical cancer. The
                        study was published in the November 21 issue of The New England Journal of
                        Medicine (NEJM).

                        The Reuters News Agency provided this lead: "A vaccine against a cervical
                        cancer-causing virus can protect young women from infection - a success
                        researchers hope will eventually allow them to prevent many cases of cervical
                        cancer."

                        The virus referred to is the human papillomavirus (HPV).

                        Reuters quoted Dr. Christopher P. Crum of Brigham and Women’s Hospital in
                        Boston as saying: "This is a great study."

                        Let’s move on. 

                        CBSNews.com’s headline asked the question: "Major Cancer Breakthrough?"
                        Then the report proceeded to quote researchers in this manner: "It’s really the
                        first time that a vaccine has been shown to prevent directly a pre-cancerous
                        condition and indirectly a cancerous condition." That quote was attributed to
                        Dr. Carol Brown, a gynacologic oncologist at Memorial Sloan Kettering
                        Cancer Center in New York.

                        Over at the New York Times, at least the headline was more circumspect:
                        "Experimental Vaccine Appears To Prevent Cervical Cancer." The "deck" or
                        the line underneath the main headline might have read this way: "Appearances
                        Can Be Deceiving." However, the Times chose to report: "The vaccine works
                        by making people immune to a sexually transmitted virus [human
                        papillomavirus] that causes many cases of the disease."

                        The Times quoted Dr. Laura A. Koutsky of the University of Washington in
                        Seattle, the study’s director, as saying: "These are tremendous results."

                        The Chicago Tribune bought the study too. Its lead paragraph referred to the
                        fact that "after decades of failure," scientists showed early success in
                        preventing human papilloma infection, "which is linked to cervical cancer."

                        Really?

                        First, Some Background And A Question Raised

                        Cervical cancer, arising in the lining of the cervix, affects about 13,000 women
                        in the U.S. each year. About 4,000 die. Worldwide, a half million get the
                        disease and 225,000 die.

                        Back in the 1970s, herpes simplex virus (HSV) was proposed as the
                        sexually-transmitted cause of cervical cancer, based mostly on population
                        studies that showed a correlation of the disease with HSV DNA. That
                        approach shifted to HPV in the 1980s, and over the years population studies
                        set the pace for the now well-accepted view that cervical cancer is strongly
                        related to the transmission of HPV. 

                        This is a group of more than 100 viruses, about 30 of which are said to be
                        linked to cervical cancer. Of these 30 or so, HPV-16 is said to be found in 50
                        percent of cervical cancers. HPV-18 accounts for another 20 percent.

                        In addition to the population studies that link HPV to cervical cancer, there is,
                        for example, research showing that HPV viral DNA can be found integrated in
                        the genetic structure of cervical cancers. 

                        Back in 1992, however, a question was raised about the dominant and
                        increasingly entrenched theory that HPV causes cervical cancer. It came from
                        Peter Duesberg and Jody Schwartz, molecular biologists at the University of
                        California at Berkeley. 

                        Among the various issues they raised about the acceptance of HPV as the
                        cause of cervical cancer was their fundamental concern that there was a lack
                        of consistent HPV DNA sequences and consistent HPV gene expression in
                        tumors that were HPV-positive. They instead suggested that "rare
                        spontaneous or chemically induced chromosome abnormalities which are
                        consistently observed in both HPV and HSV DNA-negative and positive
                        cervical cancers induce cervical cancer."

                        In short, Duesberg and Schwartz were pointing to the possibility that
                        "carcinogens may be primary inducers of abnormal cell proliferation rather
                        than HPV or HSV." And here’s the key point: "Since proliferating cells [cancer
                        cells dividing wildly] would be more susceptible to infection than resting cells,
                        the viruses would just be indicators rather than causes of abnormal
                        proliferation."

                        The concept they raised back in 1992 is still relevant today; only science has
                        gone on to assume that causation of cervical cancer has been well
                        established. Even the National Cancer Institute (NCI) says that "direct"
                        causation has not been demonstrated; however, the NCI and just about
                        everyone else works with the principle that it has been established. Lip
                        service is paid to other possible factors that may be involved in cervical
                        cancer such as environmental conditions, including smoking. Even dietary
                        factors -- particularly low levels of Vitamin A and folate -- have been
                        suggested as associated with a risk for cervical cancer. 

                        But once a vaccine to prevent HPV infection is raised as a weapon to prevent
                        cervical cancer, then it’s pretty clear that the medical Establishment has gone
                        all the way in accepting a theory. And it’s also quite evident in some of the
                        comments listed above that have been made to reporters.

                        The headline to the accompanying editorial to the study in the NEJM screams
                        out:

                            "The Beginning of the End for Cervical Cancer?" 

                        This editorial is more or less an ode to the research published. 

                        But the published research doesn’t necessarily deserve any praise. Why?
                        Because the study is a disgrace.

                        A Worthless Study

                        When I first reviewed the study, I couldn’t believe the NEJM was putting this
                        research on such a high footing -- and that includes the embarrassing
                        editorial.

                        Essentially this is what the study is about: Of 2,392 young women who were
                        entered into the study, 859 were excluded from the final data analysis -- some
                        for technical reasons and the vast majority because they were actually found
                        to be infected with HPV-16 before getting the vaccine.

                        Of 1,533 women who remained, half were given the vaccine and half the
                        placebo shot. 

                        The results were as follows: No one who was vaccinated developed an
                        HPV-16 infection or a precancerous growth. Of those who received the
                        placebo shot, 41 women became infected with HPV-16, and nine of them had
                        precancerous cervical growths. 

                        On the surface, at least interesting for an early study. But those results
                        became the focus of great jubilation.

                        But I’ll tell you this: It doesn’t take a rocket scientist to see that the study’s
                        methodology is flawed to such a degree that it doesn’t even deserve to be
                        published in some throwaway journal. But then again, the NEJM has, of late,
                        become a depository for bad science.

                        Still, given that the entire world of health journalism seems to have piled on
                        the bravos for this study and just about every vaccine specialist has come out
                        of the woodwork to applaud yet another vaccine effort, I figured that I would
                        seek out someone who has the guts to face up to the bilge that masquerades
                        as science. I therefore got hold of Howard Urnovitz, who is a scientist dealing
                        in molecular issues and a regular contributor to redflagsweekly.com.

                        His first reply was that "this is a poorly designed study that fits all-too-well into
                        the legacy of medical incompetence called vaccine research."

                        Here is what Urnovitz had to say, pretty well reaching the same conclusions
                        that I reached upon careful review of this study:

                        "These investigators initially enrolled 2,392 women to take part in the study.
                        Immediately, 36 percent were disqualified primarily because they had
                        detectable HPV markers, according to the study’s authors, who determined
                        HPV-detectability by either antibody or PCR testing. In other words, the study
                        selected for women who showed some sort of robust natural immunity that
                        kept them from expressing the HPV markers.

                        Then the study used a cancer detection method which is known to be
                        inaccurate, with a rate of false negative test results that ranges from 1
                        percent to 93 percent, despite the fact that it is the only test currently
                        available in the United States to screen women for signs of cervical cancer. (A
                        false negative result means that women who have cervical cancer or
                        precancerous tissues are not being identified when they have a Pap smear.)"

                        The women in this study are only monitored for HPV infection if they show a
                        positive Pap smear. But since even the CDC recognizes that the Pap test
                        produces a wide range of false negative results, the HPV study’s foundation --
                        the Pap test -- is so unreliable that the rest of the study is rendered highly
                        suspect.

                        "Also, the HPV test is poorly designed. A positive result was defined as any
                        PCR signal that exceeded the background PCR level associated with an
                        HPV-negative sample of human DNA. This is a risky protocol because PCR
                        tests are plagued with false positive reactions (a positive signal that is not a
                        true detection of the target). Since the authors show no data or reference to
                        data on a secondary test that confirms the gene sequence of a positive
                        signal, they cannot conclude that they are measuring HPV."

                        So here is what the study really amounts to. Again, I’ll defer to Urnovitz
                        because he lays it very cleanly on the line:

                        "The proper conclusion of this study should be: Administration of this HPV-16
                        vaccine reduced the incidence of an uncharacterized PCR signal from a poorly
                        defined cohort which was strongly biased toward a natural immunity. 

                        Finally, press suggestions or those from the authors that young girls will soon
                        be given a vaccine to prevent cervical cancer are ridiculously premature.

                        As an aside (make of it what you will), given the great new honesty in
                        medicine these days, it was noted in the NEJM that "some co-authors on the
                        study are with Merck Research Laboratories which developed the vaccine
                        and provided the funding."

                        Red Flags Weekly November 25, 2002

source: Mercola Website.

                        DR. MERCOLA'S COMMENT:
                                                                           

                        Wouldn’t it be nice if we could just get a shot, or in the future just eat a
                        plant that is reengineered to contain a vaccine that would rid of us
                        cancer? Of course it would.

                        Unfortunately that is not the way our bodies were designed. Cancer
                        prevention is not as simplistic as taking a vaccination. Maintaining a
                        high level of immune integrity is the key, and this is done through the
                        basics of emotional balancing, optimized nutrition, avoidance of toxins,
                        proper sleep, exercise and hydration.

                        This research is clearly another deceptive ploy by Merck to generate
                        revenue for their vaccine division in exchange for the delusional hope
                        that a vaccine will reduce the risk of cancer. 

                        Nicholas Regush writes an excellent review on this topic, which he is
                        quite familiar with as a result of his review of the literature on HHV6 for
                        his worthwhile book The Virus Within.